$5.87
0.77%
NYSE, Sep 17, 03:59 pm EDT. Closed.
ISIN
US05588W1080
Symbol
LEO

BNY Mellon Strategic Municipals Inc Stock price

$5.86
-0.34 5.48% 1M
-0.49 7.72% 6M
-0.50 7.86% YTD
-0.38 6.09% 1Y
+0.33 5.97% 3Y
-3.08 34.45% 5Y
-3.44 36.99% 10Y
-3.27 35.82% 20Y
NYSE, Closing price Thu, Sep 17 2026
+0.04 0.69%
ISIN
US05588W1080
Symbol
LEO

Is BNY Mellon Strategic Municipals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$368.8m
Enterprise Value
$595.4m
Net debt
$226.6m
Cash
$3.4m
Shares outstanding
62.0m
Valuation (TTM | estimate)
P/E
146.5
P/S
12.7 | -
EV/Sales
20.5 | -
EV/FCF
negative
P/B
0.9
Dividends
DPS
$0.23
Yield 1Y | 5Y
3.9% | 4.7%
Growth 1Y | 5Y
-6.6% | -10.0%
Payout 1Y | 3Y
20.7% | -163.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$29.0m | -
EBITDA
-
EBIT
$17.1m
Net Income
$2.0m
Free Cash Flow
$-22.9m
Growth (TTM | estimate)
Revenue
3.8% | -
EBITDA
-
EBIT
3.6%
Net Income
-90.0%
Free Cash Flow
-146.1%
Margin
Gross
70.4%
EBITDA
-
EBIT
59.1%
Net
6.9%
Free Cash Flow
-79.1%
Financial Health
Equity Ratio
66.8%
Return on Equity
16.4%
ROCE
2.6%
ROIC
-
Debt/Equity
0.5
More
EPS
$0.0
FCF per Share
$-0.4
Short interest
0.2%
Employees
-
Rev per Employee
-

Financial data from BNY Mellon Strategic Municipals Inc

Mar '25
+/-
%
29 29
4% 4%
100%
- Direct Costs 8.58 8.58
9% 9%
30%
20 20
2% 2%
70%
- Selling and Administrative Expenses 4.24 4.24
2% 2%
15%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 17 17
4% 4%
59%
Net Profit 2 2
90% 90%
7%

In millions USD.

Don't miss a Thing! We will send you all news about BNY Mellon Strategic Municipals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BNY Mellon Strategic Municipals Inc Stock News

Positive
Reuters
about one month ago
Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights ​to drug candidate dersimelagon from Tanabe Pharma for ‌up to $435 million in up-front and near-term milestone payments.

Company Profile

BNY Mellon Strategic Municipals, Inc. is a closed-end investment fund and investment trust. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The company was founded in 1987 and is headquartered in New York, NY.

Head office United States
Founded 1987
Website www.bny.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today